{
  "schemaVersion" : 2,
  "registerId" : "F2017C00819",
  "instrumentNumber" : "5/2015",
  "citation" : "Statement of Principles concerning soft tissue sarcoma No. 5 of 2015",
  "conditionName" : "soft tissue sarcoma",
  "effectiveFrom" : "2015-01-27",
  "standardOfProof" : "Reasonable Hypothesis",
  "icdCodes" : [ {
    "version" : "ICD-10-AM",
    "code" : "C22.3"
  }, {
    "version" : "ICD-10-AM",
    "code" : "C22.4"
  }, {
    "version" : "ICD-10-AM",
    "code" : "C30.0"
  }, {
    "version" : "ICD-10-AM",
    "code" : "C32.3"
  }, {
    "version" : "ICD-10-AM",
    "code" : "C47"
  }, {
    "version" : "ICD-10-AM",
    "code" : "C48"
  }, {
    "version" : "ICD-10-AM",
    "code" : "C49"
  } ],
  "onsetFactors" : [ {
    "paragraph" : "6(a)",
    "text" : "being:\r\n(i) on land in Vietnam; or\r\n(ii) at sea in Vietnamese waters; or\r\n(iii) on board a vessel and consuming potable water supplied on that\r\nvessel, when the water supply had been produced by evaporative\r\ndistillation of estuarine Vietnamese waters;\r\nfor a cumulative period of at least 30 days, at least five years before the\r\nclinical onset of soft tissue sarcoma",
    "definedTerms" : [ {
      "term" : "estuarine Vietnamese waters",
      "definition" : "means at least one of the waterways or\nharbours in the relevant areas described in Items 4 and 8 of Schedule 2 of the\nVEA"
    } ]
  }, {
    "paragraph" : "6(b)",
    "text" : "inhaling, ingesting or having cutaneous contact with a chemical agent\r\ncontaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) for a\r\ncumulative period of at least 250 hours, at least two years before the\r\nclinical onset of soft tissue sarcoma",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(c)",
    "text" : "having received a cumulative equivalent dose of at least 0.1 sievert of\r\nionising radiation to the affected region at least two years before the\r\nclinical onset of soft tissue sarcoma",
    "definedTerms" : [ {
      "term" : "cumulative equivalent dose",
      "definition" : "means the total dose of ionising radiation\nreceived by the particular organ or tissue from external exposure, internal\nexposure or both, apart from normal background radiation exposure in\nAustralia, calculated in accordance with the methodology set out in Guide to\ncalculation of 'cumulative equivalent dose' for the purpose of applying\nionising radiation factors contained in Statements of Principles determined\nunder Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian\nRadiation Protection and Nuclear Safety Agency, as in force on 2 August\n2017;\nNote 1: Examples of circumstances that might lead to exposure to ionising radiation include\nbeing present during or subsequent to the testing or use of nuclear weapons,\nundergoing diagnostic or therapeutic medical procedures involving ionising radiation,\nand being a member of an aircrew, leading to increased levels of exposure to cosmic\nradiation.\nNote 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass\nof a specific tissue or organ. If a tissue is exposed to multiple sources of ionising\nradiation, the various dose estimates for each type of radiation must be combined"
    } ]
  }, {
    "paragraph" : "6(d)",
    "text" : "for angiosarcoma only:\r\n(i) having received a cumulative equivalent dose of at least 0.1\r\nsievert of ionising radiation to the affected region at least one\r\nyear before the clinical onset of soft tissue sarcoma; or\r\n(ii) having lymphoedema of the affected region at the time of the\r\nclinical onset of soft tissue sarcoma",
    "definedTerms" : [ {
      "term" : "lymphoedema",
      "definition" : "means chronic oedema due to accumulation of interstitial\nfluid as a result of stasis of lymph, which is secondary to obstruction of lymph\nvessels or disorders of the lymph nodes"
    }, {
      "term" : "cumulative equivalent dose",
      "definition" : "means the total dose of ionising radiation\nreceived by the particular organ or tissue from external exposure, internal\nexposure or both, apart from normal background radiation exposure in\nAustralia, calculated in accordance with the methodology set out in Guide to\ncalculation of 'cumulative equivalent dose' for the purpose of applying\nionising radiation factors contained in Statements of Principles determined\nunder Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian\nRadiation Protection and Nuclear Safety Agency, as in force on 2 August\n2017;\nNote 1: Examples of circumstances that might lead to exposure to ionising radiation include\nbeing present during or subsequent to the testing or use of nuclear weapons,\nundergoing diagnostic or therapeutic medical procedures involving ionising radiation,\nand being a member of an aircrew, leading to increased levels of exposure to cosmic\nradiation.\nNote 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass\nof a specific tissue or organ. If a tissue is exposed to multiple sources of ionising\nradiation, the various dose estimates for each type of radiation must be combined"
    }, {
      "term" : "angiosarcoma",
      "definition" : "means lymphangiosarcoma or haemangiosarcoma"
    } ],
    "conditionVariant" : {
      "name" : "angiosarcoma",
      "variantFactors" : [ {
        "paragraph" : "(i)",
        "text" : "having received a cumulative equivalent dose of at least 0.1\r\nsievert of ionising radiation to the affected region at least one\r\nyear before the clinical onset of soft tissue sarcoma"
      }, {
        "paragraph" : "(ii)",
        "text" : "having lymphoedema of the affected region at the time of the\r\nclinical onset of soft tissue sarcoma"
      } ]
    }
  }, {
    "paragraph" : "6(e)",
    "text" : "inhaling a cumulative dose of at least 200 ppm-years of gaseous vinyl\r\nchloride at least two years before the clinical onset of soft tissue\r\nsarcoma",
    "definedTerms" : [ {
      "term" : "ppm-years",
      "definition" : "means parts per million multiplied by years of exposure"
    } ]
  }, {
    "paragraph" : "6(f)",
    "text" : "being treated with an immunosuppressive drug for at least three\r\nmonths before the clinical onset of soft tissue sarcoma",
    "definedTerms" : [ {
      "term" : "an immunosuppressive drug",
      "definition" : "means a drug or an agent which results in\nsubstantial suppression of immune responses. This definition includes\ncorticosteroids other than inhaled or topical corticosteroids, drugs used to\nprevent transplant rejection, tumour necrosis factor-Î± inhibitors and\nchemotherapeutic agents used for the treatment of cancer"
    } ]
  }, {
    "paragraph" : "6(g)",
    "text" : "being obese for a period of at least five years within the 20 years\r\nbefore the clinical onset of soft tissue sarcoma",
    "definedTerms" : [ {
      "term" : "being obese",
      "definition" : "means an increase in body weight by way of fat accumulation\nwhich results in a Body Mass Index (BMI) of 30 or greater.\n2\nThe BMI = W/H and where:\nW is the person's weight in kilograms; and\nH is the person's height in metres"
    } ]
  }, {
    "paragraph" : "6(h)",
    "text" : "for uterine sarcoma only:\r\n(i) undergoing treatment with tamoxifen for a period of at least two\r\nmonths before the clinical onset of soft tissue sarcoma; or\r\n(ii) having diabetes mellitus for at least five years before the clinical\r\nonset of soft tissue sarcoma",
    "definedTerms" : [ ],
    "conditionVariant" : {
      "name" : "uterine sarcoma",
      "variantFactors" : [ {
        "paragraph" : "(i)",
        "text" : "undergoing treatment with tamoxifen for a period of at least two\r\nmonths before the clinical onset of soft tissue sarcoma"
      }, {
        "paragraph" : "(ii)",
        "text" : "having diabetes mellitus for at least five years before the clinical\r\nonset of soft tissue sarcoma"
      } ]
    }
  }, {
    "paragraph" : "6(i)",
    "text" : "being infected with human immunodeficiency virus before the clinical\r\nonset of soft tissue sarcoma",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(j)",
    "text" : "having cutaneous scarring for at least three years before the clinical\r\nonset of soft tissue sarcoma at that site",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(k)",
    "text" : "for hepatic angiosarcoma only, being exposed to arsenic as specified\r\nbefore the clinical onset of soft tissue sarcoma, where the first\r\nexposure to arsenic occurred at least five years before the clinical onset\r\nof soft tissue sarcoma",
    "definedTerms" : [ {
      "term" : "being exposed to arsenic as specified",
      "definition" : "means:\n(a) being involved in the manufacture of pesticides containing arsenic for a\ncumulative period of at least 365 days;\n(b) consuming arsenic containing compounds (for example, Fowler's\nsolution) for a cumulative period of at least 90 days;\n(c) consuming drinking water with an average arsenic concentration of at\nleast 50 micrograms per litre for a cumulative period of at least ten\nyears;\n(d) consuming drinking water resulting in a cumulative total arsenic\nexposure equivalent to having consumed drinking water containing at\nleast 50 micrograms per litre for at least ten years;\n(e) handling pesticides containing arsenic for a cumulative period of at\nleast 365 days; or\n(f) having clinical evidence of chronic arsenic toxicity"
    }, {
      "term" : "angiosarcoma",
      "definition" : "means lymphangiosarcoma or haemangiosarcoma"
    } ],
    "conditionVariant" : {
      "name" : "hepatic angiosarcoma",
      "variantFactors" : [ ]
    }
  }, {
    "paragraph" : "6(l)",
    "text" : "for cutaneous atypical fibroxanthoma only, having chronic solar skin\r\ndamage involving the area of skin affected by the cutaneous atypical\r\nfibroxanthoma at the time of the clinical onset of soft tissue sarcoma",
    "definedTerms" : [ ],
    "conditionVariant" : {
      "name" : "cutaneous atypical fibroxanthoma",
      "variantFactors" : [ ]
    }
  } ],
  "aggravationFactors" : [ {
    "paragraph" : "6(m)",
    "text" : "inability to obtain appropriate clinical management for soft tissue\r\nsarcoma",
    "definedTerms" : [ ]
  } ]
}